United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026
United Therapeutics announced that its pivotal Phase 3 ADVANCE OUTCOMES study for ralinepag met its primary endpoint, showing a 55% reduction in the risk of clinical worsening in PAH patients. The drug also achieved statistical significance for key secondary endpoints, including a 24.3% reduction in NT-proBNP levels and a 20.4-meter improvement in six-minute walk distance.
Key figures
- Drug Name
- ralinepag
- Phase Of Trial
- Phase 3
- Nt probnp reduction
- 24.3%
- Study population size
- 687
- Primary endpoint hazard ratio
- 0.45
- Primary endpoint risk reduction
- 55%
- Clinical improvement odds increase
- 47%
- Six minute walk distance improvement
- +20.4 m
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.